Enzo Biochem (ENZ) Posts Narrower than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts ENZ Hot Sheet
Join SI Premium – FREE
Enzo Biochem, Inc. (NYSE: ENZ) reported Q3 loss of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $25.8 million versus the consensus estimate of $24.77 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
- ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c
- Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
